Hidetoshi Hayashi - Concepedia

Author

Hidetoshi Hayashi

Also Known As

H Hayashi, H. Hayashi, HIDETOSHI HAYASHI, Hayashi, Hidetoshi, Hidetoshi HAYASHI, Hidetoshi Hayashi, Nirav Asarawala, Yasushi Goto

638

Publications

13K

Citations

H-Index

Concepts

All Affiliations

Kindai University Kindai University Hospital Wakayama Medical University Shizuoka Cancer Center Sendai Kousei Hospital

About

Hidetoshi Hayashi is an author at Kindai University specializing in medicine, oncology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	31	74	6.1K
2	Health Sciences	12	13	397
3	Allergy	3	3	99
4	Engineering	1	1	81
5	Natural Sciences	1	1	41

Hidetoshi Hayashi

160

Publications

12K

Citations

H-Index

Page 1

	Year	Citations
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen, The Lancet Platinum–etoposide Versus Platinum–etoposideMedicinePharmacologyImmune Checkpoint InhibitorFirst-line Treatment	2019	2.1K
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer Koji Haratani, Hidetoshi Hayashi, Yasutaka Chiba, JAMA Oncology	2017	978
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen, The Lancet Oncology Platinum–etoposide Versus Platinum–etoposideMedicinePathologyImmune Checkpoint InhibitorFirst-line Treatment	2020	662
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration Alexander Drilon, Jeffrey W. Clark, Jared Weiss, Nature Medicine Lung CancersAntitumor ActivityMedicinePharmacologyPathology	2020	364
Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLC Byoung Chul Cho, Shun Lu, Enriqueta Felip, New England Journal of Medicine	2024	308
Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment Koji Haratani, Hidetoshi Hayashi, Taro Tanaka, Annals of Oncology Tumor Immune MicroenvironmentCancer ImmunosurveillanceMedicineImmunologyTumor Immunity	2017	291
Trastuzumab Deruxtecan in Patients With <i>HER2</i>-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial Kōichi Goto, Yasushi Goto, Toshio Kubo, Journal of Clinical Oncology	2023	250
Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in <i>EGFR</i> Mutation–Positive Non–Small Cell Lung Cancer Kohsuke Isomoto, Koji Haratani, Hidetoshi Hayashi, Clinical Cancer Research	2020	233
Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab Junko Tanizaki, Koji Haratani, Hidetoshi Hayashi, Journal of Thoracic Oncology Biomarker (Medicine)Prognostic BiomarkersOncologyMedicineBiomarker Target	2017	223
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy Helena A. Yu, Yasushi Goto, Hidetoshi Hayashi, Journal of Clinical Oncology	2023	194

Page 1